Luckey's startup raises $200 million for gene-edited military dogs

Palmer Luckey’s new company, Warhound, has secured $200 million in funding to develop genetically modified dogs for the military. The startup plans to use genetic enhancement to improve the animals’ ability to detect explosives and assist in troop protection. Reports published on October 23, 2026, confirm the size of the raise and the specific operational goals of the project.

The funding round includes investment from Sequoia. Colossal Biosciences is also involved in the initiative. That company is assisting with the technical aspects of the program, specifically the cloning and gene-editing processes required to alter the dogs' DNA.

Luckey founded Warhound to apply biotechnology to defense applications. The venture aims to create service animals with traits that are difficult to achieve through traditional breeding methods alone. The financial backing allows the company to move from concept to active development of these enhanced canines.

The move reflects a growing interest in using biological engineering for tactical purposes. By partnering with Colossal Biosciences, Warhound gains access to specialized expertise in genetic modification. This collaboration supports the company's goal of producing dogs that can perform specific military tasks with greater efficiency.

No public statements from the Department of Defense or specific military branches were included in the initial reports. The focus remains on the private sector's role in developing new tools for military use. The $200 million in capital provides Warhound with the resources to conduct its research and testing.

The project stands out for its scale and the prominence of its founder. Luckey is known for his previous work in virtual reality and space technology. His entry into the biotech and defense space marks a diversification of his portfolio of companies.